Syndax Pharmaceuticals

Historical price data

Syndax Pharmaceuticals is a clinical-stage biotech focused on developing novel inhibitors for cancers with high unmet need, primarily through its menin and BET inhibitor platforms. Its lead asset, revumenib, is a potential best-in-class menin inhibitor in late-stage development for KMT2A-rearranged and NPM1-mutant acute leukemias. The company's strategy leverages deep mechanistic insight to target key drivers of oncogenesis and fibrosis, aiming to deliver transformative therapies. With a disciplined approach to clinical development and a strong cash position, Syndax is advancing a targeted pipeline toward key regulatory milestones.

Two core platforms: Menin-KMT2A interaction inhibitors for genetically defined leukemias, and BET/CSF-1R inhibitors targeting transcriptional regulation and profibrotic macrophages in oncology and fibrosis.

Syndax is a leader in the nascent menin inhibitor space, competing primarily with Kura Oncology, with a first-mover advantage in late-stage development. In cGVHD, axatilimab faces competition from established JAK/BTK inhibitors but is differentiated by its unique CSF-1R macrophage-targeting mechanism.